Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Hematologic Oncology
10:05

Xth Eurasian Hematology-Oncology Congress

Best Abstract Presentation (Francesco Lo Coco Prize) - Adult Hematology A Retrospective Analysis of Peripheral T-Cell Lymphoma Patients: Single - Center ‘Real-Life’ Experience

FEATURING Murat Ozbalak
  • 24 views
  • July 13, 2020
07:09

Xth Eurasian Hematology-Oncology Congress

Best Abstract Presentation (Ekrem Muftuoglu Prize) - Oncology Evaluation of Secondary Hypogammaglobulinemia in Patients with Hematologic Malignancy Receiving Ibrutinib Therapy

FEATURING Serhat Çelik
  • 9 views
  • July 13, 2020
10:30

Xth Eurasian Hematology-Oncology Congress

Best Abstract Presentation (Atilla Yalcin Prize) - Transplant Is There Any Impact Of Uric Acid Levels During the Peri-Transplant Period on Acute Graft Vs. Disease Incidence and Allotransplant Outcome?

FEATURING Panayotis Kaloyannidis
  • 6 views
  • July 13, 2020
19:12

Xth Eurasian Hematology-Oncology Congress

Generic TKI’s in CML Therapy

FEATURING Tomasz Sacha
  • 4 views
  • May 28, 2020
21:40

Xth Eurasian Hematology-Oncology Congress

2019 Update on ASFA Guidelines on the Use of Therapeutic Apheresis: Incorporation of Systematic Review and Evidence-based Approaches in the Grading and Categorization of Indication

FEATURING Joseph Schwartz
  • 2 views
  • May 28, 2020
23:26

Xth Eurasian Hematology-Oncology Congress

2019 Update on Extracorporeal Photopheresis (ECP): How Much Is Enough? How and When Do We Taper? When Do We Stop? Are There Biomarkers to Follow?

FEATURING Jennifer Schneiderman
  • 5 views
  • May 28, 2020
24:16

Xth Eurasian Hematology-Oncology Congress

Update on Collections for HCP and CAR-T: T Cell CE Correlates Inversely With Peripheral Blood T Cell Count and Is Not Impacted by Blood Volumes Processed

FEATURING Anand Padmanabhan
  • 3 views
  • May 28, 2020
21:36

Xth Eurasian Hematology-Oncology Congress

How I Treat Multiple Myeloma

FEATURING Angelo Maiolino
  • 91 views
  • April 6, 2020
22:57

Xth Eurasian Hematology-Oncology Congress

Importance of MRD in Multiple Myeloma: Can MRD Guide Therapy in Newly Diagnosed Disease? Should We Start Therapy an an MRD- Patient Who Becomes MRD+?

FEATURING Evangelos Terpos
  • 13 views
  • April 6, 2020
18:10

Xth Eurasian Hematology-Oncology Congress

Impact of Continuous First-Line Therapy in the Treatment of the First Relapse in Multiple Myeloma

FEATURING Ahmad Ibrahim
  • 41 views
  • April 6, 2020
  • 1
23:38

Xth Eurasian Hematology-Oncology Congress

Therapeutic Modulation of The Pleural Effusion Environment: the Next-Gen Immunotherapy

FEATURING Vera Donnenberg
  • 13 views
  • April 6, 2020
18:57

Xth Eurasian Hematology-Oncology Congress

The Secretome of Malignant Effusions: The IL-6/sIL-6Ra Axis Appears to Be a Central Driver of the Immunosuppressive, Tumor-supportive Pleural Environment

FEATURING Albert Donnenberg
  • 17 views
  • April 6, 2020
24:57

Xth Eurasian Hematology-Oncology Congress

Are Maintenance Post-transplant Therapies Needed: Hypomethylating Agents May Modulate GVL and GVHD and Improve Post-transplant Outcome

FEATURING Khalid Halahleh
  • 20 views
  • April 6, 2020
20:18

Xth Eurasian Hematology-Oncology Congress

Will CAR T-cell Therapy Replace HSCT? The Use of CAR-T Could Further Improve HSCT Results by Reducing the Rate of Relapse Incidence

FEATURING Francesco Saglio
  • 30 views
  • March 31, 2020
25:14

Xth Eurasian Hematology-Oncology Congress

Oral Chronic GVHD Is Common Disease and May Persist for Years, Management Tailored to Individual, Oral Cancer Risk Requires Lifelong Surveillance

FEATURING Nathaniel Simon Treister
  • 23 views
  • March 31, 2020
10:40

Xth Eurasian Hematology-Oncology Congress

Analysis of PFS in CLL: Pts Who Received First-Line Bendamustine-Rituximab Depending on The Elimination Rate of The MRD and IGHV

FEATURING Iulia Miroliubova
  • 16 views
  • March 30, 2020
11:45

Xth Eurasian Hematology-Oncology Congress

Prognostic Implication of NOTCH 1 Expression Among Adult Patients with Normal Cytogenetic AML: NOTCH1 Important Poor Prognostic Marker Among AML Pts

FEATURING Ghaleb Elyamany
  • 12 views
  • March 30, 2020
16:28

Xth Eurasian Hematology-Oncology Congress

2019 SOHO Update on AML: FLT3 and IDH1/2 Inhibitors, Venetoclax, Antibodies, CAR-T CPIs, CD70 Ab / CD47 Ab, and APR 246 for p53-Mutated MDS/AML

FEATURING Guillermo Garcia-Manero
  • 194 views
  • December 9, 2019
  • 1
21:46

Xth Eurasian Hematology-Oncology Congress

Personalizing Prognosis and Treatment of MPN: Historical Milestones and Definitions, Response and Prognosis Predicting Molecular Tools

FEATURING Tariq Mughal
  • 17 views
  • December 13, 2019
23:03

Xth Eurasian Hematology-Oncology Congress

The Best Example of Precision Oncology in CML: Response to TKI Therapy is the Best Predictor of the Outcome

FEATURING Giuseppe Saglio
  • 89 views
  • December 13, 2019
22:56

Xth Eurasian Hematology-Oncology Congress

Precision Oncology in MDS: We Still Don't Know Precise Mechanism of Action of HMA or MDS Pathophysiology, IDH1/2 and DNMT3A Have Positive Impact on Response Rates

FEATURING Mustafa Çetiner
  • 18 views
  • December 13, 2019
15:40

Xth Eurasian Hematology-Oncology Congress

2019 SOHO Update on ALL: Ponatinib -Blinatumomab in Ph+, Ino / Blinatumomab + ChemoRx in Salvage and Frontline, Bcl2-Bclxl Inhibitors, and Blinatumomab SQ TIW

FEATURING Elias Jabbour
  • 108 views
  • December 13, 2019
14:17

Xth Eurasian Hematology-Oncology Congress

2019 SOHO Updates on CML: Frontline Therapy is Good, Getting Better and Safer, 2nd Line Options Grossly Equivalent, 3rd Line Ponatinib is Better, Complete Cytogenetic Response Improves Survival

FEATURING Elias Jabbour
  • 152 views
  • December 13, 2019
  • 1
19:17

Xth Eurasian Hematology-Oncology Congress

2019 SOHO Updates on MDS: Treatment of CHIP, New Approach for Anemia Luspatercept, New HMAS ASTX727 and CC-486, Targeting TP53 APR-246, Intro to ABT-199, Integration of AlloSCT, Other Targets

FEATURING Guillermo Garcia-Manero
  • 45 views
  • December 13, 2019
16:04

Xth Eurasian Hematology-Oncology Congress

St-Petersburg Hematological Centre Experience on the Use of BMT in Relapsed/Refractory Malignant Lymphomas: Brentuximab Vedotin is Safe and Effective as a Bridge Therapy and for Relapses after allo-HSC

FEATURING Natalia Mikhailova
  • 27 views
  • December 13, 2019
14:22

Xth Eurasian Hematology-Oncology Congress

Kirov Hematological Institute Analysis of Donors Register: Unrelated Donorship in Russia

FEATURING Maria Loginova
  • 4 views
  • December 13, 2019
13:40

Xth Eurasian Hematology-Oncology Congress

Bone Marrow Allogenic Transplantation in Relapsed/ Refractory Hem Malignancies: IO Is Effective Bridging Strategy, and to Treat Relapses After HSCT, alloHSCT Technology Is Improving

FEATURING Ivan Moiseev
  • 11 views
  • December 13, 2019
20:34

Xth Eurasian Hematology-Oncology Congress

Should ALL Treatment be Driven by MRD Detection? IOs Result in Higher MRD vs. Chemo, Frontline IO May Alter Treatment Paradigm

FEATURING Dieter Hoelzer
  • 23 views
  • December 13, 2019
20:45

Xth Eurasian Hematology-Oncology Congress

2019 Therapy of Ph+ ALL: Which TKIs, Dosing and Schedule, Intensity, Optimal Rx for Elderly, MRD, Stem Cell Transplant, and TKI Maintenance

FEATURING Oliver G. Ottmann
  • 104 views
  • December 13, 2019
12:21

Xth Eurasian Hematology-Oncology Congress

Ph-like ALL Should Be Treated as the Other B ALL After Demonstration of the Right Target and Best Trial / Registry Context

FEATURING Oliver G. Ottmann
  • 19 views
  • December 13, 2019
24:55

Xth Eurasian Hematology-Oncology Congress

Overview of Current Therapeutic Options in AML of Young Adults: New Drugs Like Venetoclax, Midostaurin, or Enasidenib Have Transformed the Paradigm of Treatment

FEATURING Mehmet Yilmaz
  • 187 views
  • December 20, 2019
22:53

Xth Eurasian Hematology-Oncology Congress

Risk Stratification and Treatment of CLL: If New Drugs Available, 17p / TP53 Should Be Tested at 1st-Line and Relapse/Refractory

FEATURING Robin Foa
  • 241 views
  • December 20, 2019
22:05

Xth Eurasian Hematology-Oncology Congress

Therapeutic Approach for CLL Biomarkers: Low-Risk Should Be Treated w/ anti-CD20+Chlorambucil, High-Risk w/ BCRis, Venetoclax, or Combos

FEATURING Panayiotis Panayiotidis
  • 227 views
  • December 20, 2019
  • 1
22:53

Xth Eurasian Hematology-Oncology Congress

New Drugs Have an Established Role in CLL: BCR and BCL2 Inhibitors (Ibrutinib, Idelalisib / Rituximab, Venetoclax +/- Rituximab), New Agents Combos, and Their Effect on OS and PFS

FEATURING Robin Foa
  • 211 views
  • December 20, 2019
13:19

Xth Eurasian Hematology-Oncology Congress

Moscow National Hematological Centre Experience on the Role and Place of Auto-HSCT in MM: # of Stem Cell Transplantations Increased in Russia

FEATURING Larisa Mendeleeva, Maxim Solovev
  • 6 views
  • December 30, 2019
07:20

Xth Eurasian Hematology-Oncology Congress

Ph-like ALL Therapy Should Be Different From the Other B-ALL: Targeted Therapy Consequence w/ TKI Are JAK2 Added to the Relapse Regimen or IO Approach

FEATURING Dieter Hoelzer
  • 19 views
  • December 30, 2019
23:09

Xth Eurasian Hematology-Oncology Congress

Hemostasis Changes in Paroxysmal Nocturnal Hemoglobinuria: Is PNH a Prothrombotic State?

FEATURING Pierre A. Toulon
  • 28 views
  • December 30, 2019
26:52

Xth Eurasian Hematology-Oncology Congress

Managing Paroxysmal Nocturnal Hemoglobinuria: Chronic Complement-Mediated Hemolysis Is the Underlying Cause of Progressive Morbidities and Mortality in PNH

FEATURING Bulent Antmen
  • 50 views
  • December 30, 2019
21:11

Xth Eurasian Hematology-Oncology Congress

Eosinophilia and Mastocytosis: TKIs are SOC for PDGFRa/b Mutations, JAKifor Rare JAK Cases, FGFR Mutations Are Challenging, Midostaurin as SoC for Mastocytosis

FEATURING Hanan Hamed
  • 22 views
  • December 30, 2019
19:25

Xth Eurasian Hematology-Oncology Congress

Approaching Consensus in Immune Thrombocytopenic Purpura: Adult ITP and "Problems w/ Traditional Treatments, TPO-RAs, ITP in Pregnancy and Childhood, Health-Related QoL

FEATURING Drew Provan
  • 22 views
  • December 30, 2019